Cargando…

Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report

Hyperfibrinolysis induced by factor XIII deficiency (FXIIID) is extremely rare, and patients with no manifestations of active bleeding can easily and frequently be neglected in clinical practice, leading to a missed diagnosis. Herein, we report a rare case of idiopathic FXIIID with secondary hyperfi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Lingsu, Li, Dengju, Ding, Meiqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302284/
https://www.ncbi.nlm.nih.gov/pubmed/35866832
http://dx.doi.org/10.1097/MD.0000000000029446
_version_ 1784751602725289984
author Gao, Lingsu
Li, Dengju
Ding, Meiqi
author_facet Gao, Lingsu
Li, Dengju
Ding, Meiqi
author_sort Gao, Lingsu
collection PubMed
description Hyperfibrinolysis induced by factor XIII deficiency (FXIIID) is extremely rare, and patients with no manifestations of active bleeding can easily and frequently be neglected in clinical practice, leading to a missed diagnosis. Herein, we report a rare case of idiopathic FXIIID with secondary hyperfibrinolysis. PATIENT CONCERNS: A 69-year-old man presented with ecchymosis of the right arm and chest wall. DIAGNOSIS: Considering the clinical picture, coagulation function test results, and FXIII activity, the patient was finally diagnosed with hyperfibrinolysis secondary to acquired factor XIII deficiency. INTERVENTIONS: The patient was treated with fresh frozen plasma, aminomethylbenzoic acid, a prothrombin complex, etamsylate, dexamethasone, and cryoprecipitate. OUTCOMES: The patient improved and was discharged after factor replacement therapy, and no further bleeding was reported 1 month after discharge. CONCLUSION: This case report illustrates that the complications of Factor XIII deficiency may include hyperfibrinolysis. Since timely diagnosis of FXIIID is challenging, detailed coagulation factor examinations are needed for definitive diagnosis. It has been suggested that gene testing and antibody testing can help in diagnosis. If ideal treatment is not available, alternative treatment should be provided to reduce bleeding.
format Online
Article
Text
id pubmed-9302284
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-93022842022-08-03 Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report Gao, Lingsu Li, Dengju Ding, Meiqi Medicine (Baltimore) Research Article Hyperfibrinolysis induced by factor XIII deficiency (FXIIID) is extremely rare, and patients with no manifestations of active bleeding can easily and frequently be neglected in clinical practice, leading to a missed diagnosis. Herein, we report a rare case of idiopathic FXIIID with secondary hyperfibrinolysis. PATIENT CONCERNS: A 69-year-old man presented with ecchymosis of the right arm and chest wall. DIAGNOSIS: Considering the clinical picture, coagulation function test results, and FXIII activity, the patient was finally diagnosed with hyperfibrinolysis secondary to acquired factor XIII deficiency. INTERVENTIONS: The patient was treated with fresh frozen plasma, aminomethylbenzoic acid, a prothrombin complex, etamsylate, dexamethasone, and cryoprecipitate. OUTCOMES: The patient improved and was discharged after factor replacement therapy, and no further bleeding was reported 1 month after discharge. CONCLUSION: This case report illustrates that the complications of Factor XIII deficiency may include hyperfibrinolysis. Since timely diagnosis of FXIIID is challenging, detailed coagulation factor examinations are needed for definitive diagnosis. It has been suggested that gene testing and antibody testing can help in diagnosis. If ideal treatment is not available, alternative treatment should be provided to reduce bleeding. Lippincott Williams & Wilkins 2022-07-22 /pmc/articles/PMC9302284/ /pubmed/35866832 http://dx.doi.org/10.1097/MD.0000000000029446 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gao, Lingsu
Li, Dengju
Ding, Meiqi
Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report
title Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report
title_full Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report
title_fullStr Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report
title_full_unstemmed Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report
title_short Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report
title_sort hyperfibrinolysis secondary to acquired factor xiii deficiency a case report
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302284/
https://www.ncbi.nlm.nih.gov/pubmed/35866832
http://dx.doi.org/10.1097/MD.0000000000029446
work_keys_str_mv AT gaolingsu hyperfibrinolysissecondarytoacquiredfactorxiiideficiencyacasereport
AT lidengju hyperfibrinolysissecondarytoacquiredfactorxiiideficiencyacasereport
AT dingmeiqi hyperfibrinolysissecondarytoacquiredfactorxiiideficiencyacasereport